Published in Cancer Weekly, November 22nd, 2011
"Moreover, recent studies identified illegitimate ß-catenin signaling as relevant hit in a considerable subset of patients. To further investigate the currently...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.